TY - JOUR
T1 - Diagnostic performance of a novel multiplex immunoassay in colorectal cancer
AU - Dressen, Katja
AU - Hermann, Natalie
AU - Manekeller, Steffen
AU - Walgenbach-Bruenagel, Gisela
AU - Schildberg, Frank A.
AU - Hettwer, Karina
AU - Uhlig, Steffen
AU - Kalff, Jörg C.
AU - Hartmann, Gunther
AU - Holdenrieder, Stefan
PY - 2017/5
Y1 - 2017/5
N2 - Background/Aim: We evaluated the diagnostic performance of a newly-launched magnetic bead-based multiplex immunoassay panel including cancer, apoptotic, immunological and angiogenesis biomarkers for differential diagnosis of colorectal cancer (CRC). Patients and Methods: Serum samples of 106 individuals comprising of 35 patients with CRC (23 colon cancer, 12 rectal cancer), 20 with respective benign colorectal diseases and 51 healthy controls were analyzed by the Milliplex™ MAP Human Circulating Cancer Biomarker Panel 1 run on the Bio-Plex™ 200 System. Results: IL-8, CEA, HGF, TNFα, CYFRA 21-1, OPN, TGFα, CA 19-9, CA 125, AFP and sFas showed significantly higher levels in cancer samples compared to healthy controls. It is noteworthy that comparing CRC and benign colorectal disease samples, many immunological and cell death markers were elevated as well. Exclusively, six markers were distinguished significantly between both groups: CEA showed the best performance in differential diagnosis reaching an AUC of 0.859 in ROC curve followed by CA 19-9, CYFRA 21-1, IL-8, CA 125 and OPN reaching AUCs between 0.696 and 0.744. Correlation with tumor stage was found for CEA, sFas and CYFRA 21-1. Finally marker scores were assembled showing that a combination of CEA and CA 19-9 had a higher AUC (0.893) compared to the biomarkers alone. Conclusion: Differential diagnosis of CRC can be improved by new biomarker classes and their combination assessed by novel multiplex immunoassay.
AB - Background/Aim: We evaluated the diagnostic performance of a newly-launched magnetic bead-based multiplex immunoassay panel including cancer, apoptotic, immunological and angiogenesis biomarkers for differential diagnosis of colorectal cancer (CRC). Patients and Methods: Serum samples of 106 individuals comprising of 35 patients with CRC (23 colon cancer, 12 rectal cancer), 20 with respective benign colorectal diseases and 51 healthy controls were analyzed by the Milliplex™ MAP Human Circulating Cancer Biomarker Panel 1 run on the Bio-Plex™ 200 System. Results: IL-8, CEA, HGF, TNFα, CYFRA 21-1, OPN, TGFα, CA 19-9, CA 125, AFP and sFas showed significantly higher levels in cancer samples compared to healthy controls. It is noteworthy that comparing CRC and benign colorectal disease samples, many immunological and cell death markers were elevated as well. Exclusively, six markers were distinguished significantly between both groups: CEA showed the best performance in differential diagnosis reaching an AUC of 0.859 in ROC curve followed by CA 19-9, CYFRA 21-1, IL-8, CA 125 and OPN reaching AUCs between 0.696 and 0.744. Correlation with tumor stage was found for CEA, sFas and CYFRA 21-1. Finally marker scores were assembled showing that a combination of CEA and CA 19-9 had a higher AUC (0.893) compared to the biomarkers alone. Conclusion: Differential diagnosis of CRC can be improved by new biomarker classes and their combination assessed by novel multiplex immunoassay.
KW - Biomarker
KW - CA 19-9
KW - CEA
KW - Colorectal cancer
KW - IL-8
KW - Multiplex immunoassay
KW - Tumor marker
UR - http://www.scopus.com/inward/record.url?scp=85019168030&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11588
DO - 10.21873/anticanres.11588
M3 - Article
C2 - 28476816
AN - SCOPUS:85019168030
SN - 0250-7005
VL - 37
SP - 2477
EP - 2486
JO - Anticancer Research
JF - Anticancer Research
IS - 5
ER -
